Literature DB >> 18566992

Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland.

Maarit Leinonen1, Laura Kotaniemi-Talonen, Ahti Anttila, Tadeusz Dyba, Jussi Tarkkanen, Pekka Nieminen.   

Abstract

A persistent high-risk human papillomavirus (hrHPV) infection is a necessary condition for developing a cervical intraepithelial neoplasia and cervical cancer. The viral aetiology in cervical carcinogenesis has stimulated attempts to use HPV DNA detection in cervical cancer screening. In Finland there is an ongoing study assessing the benefits of primary HPV DNA testing in the setting of centrally organised mass screening for cervical cancer. Here we present the age-specific prevalence of hrHPV infection and associated sociodemographic factors of 16,895 women aged 25-65 years attending the 5-yearly cervical cancer screening between years 2003 and 2004. The overall hrHPV prevalence rate was 7.5%. The peak prevalence at the age group of 25-29 was 24.1% decreasing steadily thereafter to approximately 2.9% in women aged 65 years. Young age and marital status were the main determinants for oncogenic HPV types. Our study confirms the inverse relationship between age and hrHPV prevalence reported in many developed countries. As our prevalence rates and hence background risk for cervical cancer are not lower than in other European countries, it is likely that our lowest cervical cancer burden in Europe is due to health care actions justifying the organised cervical cancer screening. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566992     DOI: 10.1002/ijc.23670

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014-2015.

Authors:  Monserrat Balanda; Andrea Quiero; Nicolás Vergara; Gloria Espinoza; Héctor San Martín; Giovanna Rojas; Eugenio Ramírez
Journal:  Med Microbiol Immunol       Date:  2016-08-18       Impact factor: 3.402

2.  A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Authors:  Gina S Ogilvie; Dirk J van Niekerk; Mel Krajden; Ruth E Martin; Thomas G Ehlen; Kathy Ceballos; Stuart J Peacock; Laurie W Smith; Lisa Kan; Darrel A Cook; Wendy Mei; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  BMC Cancer       Date:  2010-03-24       Impact factor: 4.430

3.  Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia.

Authors:  Anneli Uusküla; Mart Kals; Liina Kosenkranius; Louise-Anne McNutt; Jack DeHovitz J
Journal:  BMC Infect Dis       Date:  2010-03-11       Impact factor: 3.090

4.  Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach.

Authors:  Simopekka Vänskä; Kari Auranen; Tuija Leino; Heini Salo; Pekka Nieminen; Terhi Kilpi; Petri Tiihonen; Dan Apter; Matti Lehtinen
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

5.  Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.

Authors:  Ahti Anttila; Laura Kotaniemi-Talonen; Maarit Leinonen; Matti Hakama; Pekka Laurila; Jussi Tarkkanen; Nea Malila; Pekka Nieminen
Journal:  BMJ       Date:  2010-04-27

6.  Estimation of the prevalence and distribution of HPV genotypes and identification of related risk factors among Turkish women.

Authors:  Mehmet Kulhan; Nur G Kulhan; Yasemin Seven; Umit A Nayki; Cenk Nayki; Nahit Ata; Pasa Ulug
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

7.  Community-Based Prevalence of Genital Human Papilloma Virus (HPV) Infection: a Systematic Review and Meta-Analysis

Authors:  Sasidharanpillai Sabeena; Parvati V Bhat; Veena Kamath; Shashikala K Bhat; Sreekumaran Nair; Ravishankar n; Kiran Chandrabharani; Govindakarnavar Arunkumar
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.